Frontlight ResearchEarly access
CompletedNo phase
DISSECT-N Post Market Data Collection Registry
Key facts
- Who runs it
- Medtronic Cardiovascular
- Where
- Albany, Ann Arbor, Atlanta, Birmingham, Charleston, Charlotte, Gainesville, Harrisburg, New York, Norfolk, Philadelphia, and Plano, United StatesSee the 12 sitesAlso in 9 other countries, 10 sites
- Trial code
- Status
- Completed
- People taking part
- 102 people enrolled
- Started
- 25 Jun 2020
- Ended
- 5 Jul 2024
- Type of study
- Observational
- Treatments tested
- Valiant Navion Thoracic Stent Graft System
- Record updated
- 3 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Subject is ≥18 years old
- Subject was treated in the last 7 days, or is intended to be treated, with the Valiant Navion Thoracic Stent Graft System for a dissection in the thoracic aorta
- Subject is willing to comply with standard of care clinical follow-up
- Subject or legal representative or consultee, as applicable has consented for study participation and signed the approved Informed Consent
Who cannot take part
- Subject is participating in an investigational drug or device study which may bias or interfere with the endpoints and follow-up of this study
- Subject has an active COVID-19 infection or relevant history of COVID-19. Relevant history of COVID-19 is defined as availability of a positive COVID-19 test with sequela or hospitalization for treatment of COVID-19. Subjects with a positive COVID-19 test who were asymptomatic or had mild symptoms should be excluded only if the positive test was less than 3 months prior to enrollment
- Subject is pregnant (not an exclusion if allowed per local regulatory requirements, pregnancy test to be performed where required)
Where in United States
Also in 9 other countries, 10 sites
- Albany Medical CenterAlbany, United States
- University of Michigan Health System - University HospitalAnn Arbor, United States
- Emory University HospitalAtlanta, United States
- University of Alabama At Birmingham HospitalBirmingham, United States
- Medical University of South CarolinaCharleston, United States
- Atrium Health's Carolinas Medical CenterCharlotte, United States
- University of Florida Health Shands HospitalGainesville, United States
- UPMC Pinnacle Harrisburg CampusHarrisburg, United States
- Northwell Health- Lenox Hill HospitalNew York, United States
- Sentara Norfolk General HospitalNorfolk, United States
- Hospital of the University of PennsylvaniaPhiladelphia, United States
- Baylor - PlanoPlano, United States
About the trial
What the trial wants to find out
DISSECT-N is a post-market registry designed to assess real-world safety and effectiveness of Valiant Navion Thoracic Stent Graft System in the treatment of thoracic aortic dissections in real world practice.
Treatments tested
- Valiant Navion Thoracic Stent Graft System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- DISSECT-N (Dissection Navion Registry)
- Record updated
- 3 July 2025